Premium
Ascent Capital-backed Naari Pharma Pvt. Ltd is set to acquire a portfolio of abbreviated new drug applications (ANDAs) from a drugmaker that's also backed by private equity investors, according to a person close to the development. Naari, through its wholly owned subsidiary Naari Pte Ltd, is acquiring 10 ANDAs from Intas ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
